Cancer survivor 'e-Patient Dave' has a bit of advice for all of us New Haven Register “Healthcare is not a spectator sport,” according to “e-Patient Dave” a cancer survivor and fascinating speaker and author.
As an oncologist, if I had to come up with something that our field should get rid of, it would be our language, or more specifically, the often imprecise, obscure, and baffling word choices that permeate our consultation notes and other communications.
Macmillan’s new report ‘Improving Care for People with Cancer: putting cancer patient experience at the heart of the NHS‘ calls for every person diagnosed with cancer to be treated with dignity and respect throughout their cancer journey. However, the sad reality is that many people have a poor experience of care as shown in the latest results of the National Cancer Patient Experience Survey.
The survey provides insights into the care and treatment experienced by cancer patients in155 NHS Hospital Trusts across England, including some patients:
Not fully understand their diagnosisNot being asked their preferred name they wanted to be called byPeople treating and caring for them not always working well togetherNot being given written information on their condition or their operationFeeling they are not involved in decisions about their treatment
The new report calls on the Government and the NHS to ensure that cancer patient experience has the same weight as clinical effectiveness and patient safety. It also urges the NHS to deliver coordinated and improved communication between staff and patients.
New strategies for delivering cancer follow-up care are needed. We surveyed primary care providers (PCPs) and oncologists to assess how physician attitudes toward and self-efficacy with cancer follow-up affect preferences for different cancer survivorship models
Marie Ennis-O'Connor's insight:
Conclusions and Implications for Cancer Survivors
PCPs and oncologists have different preferences for models of cancer survivorship care. Prior involvement with cancer surveillance was one of the strongest predictors of PCPs’ willingness to assume this responsibilit
Overall survival rates are similar in pregnant women with breast cancer and in nonpregnant women with the disease when both groups receive the same treatment, results from an international study have shown (JCO 2013;31:2532-2539).
Depression is a serious illness that can have a major impact on an individual's quality of life. In fact, 15-25% of people diagnosed with cancer also suffer from depression. This is more than double that of the general population.
Satisfying patients is increasingly important, but figuring out how to do so is a challenge.
Many hospitals, including the Cleveland Clinic, are implementing a variety of strategies to improve the patient experience —an issue that’s rapidly becoming a top priority in health care. The Accountable Care Act now links performance related to patient-experience metrics to reimbursement. For the first time, the pay of hospitals and eventually individual providers will be partly based on how they are rated by patients.
Few disagree on the importance and the need to be more patient centric, but what exactly is the “patient experience”?
A type of mindfulness meditation has a moderate to large positive impact on the mental health of women affected by breast cancer, a recent analysis published in Psycho-Oncology suggests. Researchers examined data from several published studies to determine the effectiveness of mindfulness-based stress reduction (MBSR)—a kind of focused, non-judgmental attention on the present—at reducing stress, anxiety, and depression in persons diagnosed with breast cancer.
Your pathology report is an important document in the process of making your diagnosis. It's written in very technical terms, but here's a guide to understanding that all those big words and medical jargon means.
In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto, California.
Marie Ennis-O'Connor's insight:
Key Points:HER2-positive breast cancer will cease to be a public health issue once the 3-year disease-free survival benchmark of 92% is passed.BRCA testing will become widespread, resulting in more imaging, more prophylactic surgery, and a modest reduction in systemic treatment.Targeting proliferation and survival pathways will continue to be important.Cancer genomics will become ubiquitous, but this will create new obstacles for oncologists.Novel ways of targeting dormant micrometastases will need to be addressed.